视神经炎
医学
视神经脊髓炎
多发性硬化
髓鞘少突胶质细胞糖蛋白
视力
横贯性脊髓炎
临床孤立综合征
磁共振成像
脱髓鞘病
脱髓鞘病
儿科
急性播散性脑脊髓炎
视神经
眼科
脊髓炎
疾病
髓鞘
伊库利珠单抗
颅神经疾病
年轻人
作者
Lydia Marcus,Andrew Van,Tanya A. Correya,Sanford R Williams,Miguel Arias,Hazel Quesada-Leitón,Immaculada B. Aban,Robert G. Tauscher,Jayne Ness
标识
DOI:10.1177/08830738251405681
摘要
IntroductionOptic neuritis (ON) is an acquired demyelinating syndrome and the most common cause of acute optic nerve inflammation in children and adults. This study describes the clinical and diagnostic features, visual outcomes, and relapse risk of children presenting with their first ON episode.MethodsWe prospectively identified 50 children presenting with ON as their first demyelinating event. Patients underwent both serum myelin oligodendrocyte glycoprotein (MOG) and aquaporin-4 (AQP4) antibody screening (n = 42) or were diagnosed with AQP4-seropositive neuromyelitis optica spectrum disorder (NMOSD) without MOG testing (n = 8). We analyzed demographics, antibody status, magnetic resonance imaging (MRI) findings, treatments, relapses, and visual disability.ResultsSubjects were stratified by diagnosis into idiopathic ON (n = 6), MOG antibody disease (n = 20), multiple sclerosis (n = 11), and NMOSD (n = 13). Females comprised 66% of the cohort. The mean age at onset was 12 years, and Black patients represented 48% of the cohort. Decreased visual acuity was nearly universal (96%). The logMAR of the worst eye at onset was most severe in NMOSD (3.1) and mildest in idiopathic ON (1.3). Ninety percent received intravenous steroids as acute treatment. Visual recovery varied by diagnosis, with mean improvement of 1.5 logMAR. Half (n = 25) experienced relapses, most commonly ON (19 of 25) or longitudinally extensive transverse myelitis (9 of 25). NMOSD patients had the highest relapse rates and poorest visual outcomes.ConclusionPediatric ON often leads to chronic demyelinating conditions. Visual recovery is overall good, but patients with NMOSD have worse visual outcomes and higher relapse rates.
科研通智能强力驱动
Strongly Powered by AbleSci AI